2023 was a difficult year for the life science industry. The financing environment was slow, and IPOs were nearly nonexistent. However, the outlook for 2024 is much more optimistic.
Join Life Science Washington Institute for a discussion with Fenwick capital markets partner Amanda Rose and financing partner Kat Duncan on the current state of the life sciences industry and the trends and challenges shaping the financial landscape in 2024 and beyond.